

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20	A1	(11) International Publication Number: WO 98/52546 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/US98/10661 (22) International Filing Date: 22 May 1998 (22.05.98) (30) Priority Data: 08/861,485 22 May 1997 (22.05.97) US (71)(72) Applicant and Inventor: GORBACH, Sherwood, L. [US/US]; 31 Perry Lane, Weston, MA 02193 (US). (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF ISOFLAVONOIDS IN THE TREATMENT OR PREVENTION OF POSTPARTUM DEPRESSION (57) Abstract A method of treating or preventing postpartum depression by administration of a composition containing one or more purified, naturally-occurring isoflavonoids.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**USE OF ISOFLAVONOIDS IN THE TREATMENT OR
PREVENTION OF POSTPARTUM DEPRESSION**

5

BACKGROUND OF THE INVENTION

The present invention relates to therapies for the prevention and treatment of postpartum depression, as well as other psychological disturbances that develop after childbirth.

It has long been recognized that psychological disturbances are very common in the postpartum period, usually beginning within 6 weeks after delivery. The psychological conditions can range from "maternity blues," which are usually mild, to a more severe depression, which is known to occur in fully 10% of postpartum women. Depression can have psychological effects that last for several months and occasionally even longer. A related concern is the impaired cognitive abilities and delayed social development that can be seen in the children of women who have experienced postpartum depression. At least a part of the explanation for postpartum depression is the changing hormone milieu in the woman's body following childbirth. Estrogen hormone achieves and maintains a high level during pregnancy and then drops precipitously within 48 hours after delivery to nearly the follicular level, which is the lowest level in a normally menstruating woman. This causes an acute estrogen withdrawal state, which could have effects on psychological and mental functioning. In this regard postpartum depression has been treated successfully with estrogen. In other reports estrogen has been administered immediately after childbirth to prevent recurrence of depression and other psychological disorders in women who are at risk of developing these problems in the postpartum period. Various antidepressant drugs, such as lithium, tricyclic compounds and serotonin-specific reuptake inhibitors (SSRI), have

-2-

been used in postpartum depression with varying degrees of success. There is, however, concern about their side effects and their safety in breastfeeding women. Treatment with large doses of estrogen is also a concern in breastfeeding women. Safer, effective therapies for treating and preventing
5 postpartum depression continue to be sought.

SUMMARY OF THE INVENTION

The invention features a method of treating or preventing postpartum depression in a woman who has recently given birth to a baby; the method involves administering to the woman, within six weeks (and preferably, within
10 24, or even 12, hours) a composition containing one or more purified isoflavonoids selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol. Preferably, the composition is administered orally, providing a dosage of at least 20 mg of total isoflavonoid per serving. The orally-administerable
15 composition can be a non-naturally occurring dietary product such as a confectionary bar, cereal, biscuit, or beverage. Alternatively, the composition can take the form of a medicament such as a pill, capsule, tablet, powder, or syrup, in which the total isoflavonoid is present in at least an amount of 20 mg per unit dose. Preferably, the dietary product or medicament is orally
20 consumed by the patient once, twice, or three times per day, to provide a daily oral isoflavonoid dose of between 20 and 300 mg. Preferably, the oral ingestion of the composition is sufficient to produce a transient concentration in the bloodstream of the woman of at least 50 nm of total isoflavonoid per liter of blood. By "purified" isoflavonoid is meant an isoflavonoid in more
25 concentrated form than occurs in plants.

The isoflavonoids can also be administered in the form of a topical medicament applied directly to the skin; the medicament is composed of a

-3-

dermatologically acceptable base substance admixed with the isoflavonoids; preferably, the topically applied composition contains between 1 and 40 mg isoflavonoid per gram of base. In one embodiment, the medicament forms part of a transdermal delivery system or patch, which is applied to the skin once,
5 twice, or three times per day.

Other features and advantages of the invention will be apparent from the following Detailed Description thereof, and from the claims.

DETAILED DESCRIPTION

Isoflavonoids are naturally occurring substances, found primarily in soy
10 beans. These compounds can also be found in high concentrations in red clover and in lower amounts in many other types of plants. An isoflavonoid-containing fraction useful in the invention can be extracted from a soy or plant product. It is preferred that the isoflavonoids be extracted and concentrated from soy bean or soy powder, but other plants such as clover can be used.
15 Isoflavonoids are also available commercially in substantially pure form. The concentrated isoflavonoid is preferably included in a food carrier to form a dietary product. Any type of palatable carrier may be used, but as the isoflavonoid concentrate has a strong flavor, it is preferred that the carrier include suitable flavorings to impart a different, more palatable flavor. The
20 dietary product may be any type of food product, e.g., a confectionary bar, biscuit, cereal, or beverage.

It is preferred that the dietary product contain at least 20 mg/serving total isoflavonoids. The isoflavonoid concentrate included in the dietary product preferably includes a blend of isoflavonoids with genistein, daidzein,
25 biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol; these may be administered alone or in combination. Preferably, a dietary product containing the preferred dosage of isoflavonoids is consumed at least once per

-4-

day, more preferably 2, or 3 times per day for more severe symptoms, to provide a daily oral isoflavonoid dose of 20-300 mg, more preferably 30-75 mg.

The isoflavonoid also can be administered, preferably in similar
5 dosages, in medicament form, e.g., mixed with a pharmaceutically acceptable carrier to form a pill, tablet, capsule or powder, or a liquid or syrup formulation. A topical medicament form can also be included in a transdermal delivery system or patch such as those that are well-known for the delivery of sustained doses of nicotine or estrogen.

10 When isoflavonoids are fed to healthy American adults, the absorption into the bloodstream is 10 to 20% of the amount consumed. This produces blood levels of isoflavonoids 200 to 2000 times higher than the levels of the most active natural estrogen in women, estradiol. It is known that the estrogenic activity of isoflavonoids is about 1000 to 10,000 lower than that of
15 estrogen contained in estrogen replacement therapy. These determinations indicate that consumption of isoflavonoids in dosages of 20 to 50 mg per day provides blood levels with estrogenic activity in the range of that found with estrogen replacement therapy.

Isoflavonoids have similar chemical properties to estrogens, specifically
20 they are poorly soluble in water but are readily soluble in alcohol or organic solvents. For topical application in a transdermal delivery system or patch, isoflavonoid is mixed in a conventional dermatologically acceptable base with ingredients such as alcohol, mineral oil, glyceryl monostearate, an ether complex of fatty acids, acetyl alcohol, lanolin, propylene glycol, stearyl
25 alcohol, or sodium lauryl sulfate. The dose of isoflavonoid in the topical form is 1 to 40 mg per gram of the base.

Other embodiments are within the claims.

-5-

We claim:

1. Use of a composition comprising one or more purified isoflavonoids selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitin, and equol in the preparation of
5 a medicament for treating or preventing postpartum depression in a woman who has recently given birth to a baby in an amount sufficient to produce a transient concentration in the bloodstream of said woman of at least 50 nanomoles/l.
2. Use of claim 1 wherein said composition is formulated to be
10 administered orally, in a dosage of at least 20 mg of isoflavonoid per serving.
3. Use of claim 1 wherein said composition is in the form of a non-naturally occurring dietary product.
4. Use of claim 3 wherein said isoflavonoid contains at least 20 mg/serving of said isoflavonoid.
- 15 5. Use of claim 3 wherein said dietary product is a confectionary bar.
6. Use of claim 3 wherein said dietary product is a cereal.
7. Use of claim 3 wherein said dietary product is a biscuit.
8. Use of claim 3 wherein said dietary product is a beverage.
9. Use of claim 1 wherein said composition is in the form of a

-6-

medicament.

10. Use of claim 9 wherein said composition contains at least 20 mg/unit dose of isoflavonoid.

11. Use of claim 9 wherein said medicament is in the form of a pill,
5 capsule, tablet, powder, or syrup.

12. Use of claim 1 wherein said composition is formulated to be administered in the form of a topical medicament applied directly to the skin surface, said medicament comprising a dermatologically acceptable base substance carrying said isoflavonoid.

10 13. Use of claim 12 wherein said composition contains between 1 and 40 mg of isoflavonoid per gram of base.

14. Use of claim 12 wherein said medicament forms part of a transdermal delivery system or patch.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/10661

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/20

US CL : 424/464

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/464

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

isoflavonoids, postpartum depression, estrogen, transdermal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,569,459 A (SHLYANKEVICH) 29 October 1996, column 1, lines 19-25; column 4, line 65 through column 6, line 5.	1-11
Y	US 5,516,528 A (HUGHES et al.) 14 May 1996, column 5, lines 52-57.	12-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 AUGUST 1998

Date of mailing of the international search report

01 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GABRIELLE BROUILLETTE

Telephone No. (703) 308-1235